Filtered By:
Source: Mass Device
Therapy: Pain Management
This page shows you your search results in order of date.
Order by Relevance | Date
Total 6 results found since Jan 2013.
Medtronic wins CE Mark for Intellis SCS, PNS systems
Medtronic (NYSE:MDT) said today it won CE Mark approval in the European Union for its Intellis spinal cord stimulation and peripheral nerve stimulation systems designed to treat chronic pain.
The Fridley, Minn.-based company touted the Intellis as the world’s smallest fully implantable SCS neurostim. The newly-cleared system includes improved battery performance and is managed through the use of a Samsung Galaxy Tab S2 tablet.
“Medtronic’s goal is to simplify treatment and improve the patient experience with personalized therapy that provides long-term pain relief and helps restore function. The launch ...
Source: Mass Device - November 6, 2017 Category: Medical Devices Authors: Fink Densford Tags: Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance Medtronic Source Type: news
7 ways neurostimulation could make our lives better
[Image from dierk schaefer on Flickr]Neurostimulation is being used for a lot of different things that go beyond motor disorders and diseases. Neurostimulation is used to stimulate certain parts of the brain’s nervous system. It can be invasive with implants or it can be non-invasive with electrode-filled caps and ear clips.
The neurostimulation market was worth an estimated $1.9 billion in 2016 and expected to double to almost $4 billion by 2025, according to a ReportBuyer analysis. The continuously growing range of applications and updates in the technology are contributing to the fast growth.
From devices to tr...
Source: Mass Device - July 27, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Neurological Neuromodulation/Neurostimulation Pain Management Research & Development Cleveland Clinic Hartford Healthcare Massachusetts Institute of Technology Medtronic Northwestern University University of Washington Source Type: news
7 medtech stories we missed this week: June 2, 2017
[Photo from unsplash.com]From Implandata receiving CE Marking to Inolife eyeing up-listing, here are 7 medtech stories we missed this week but thought were still worth mentioning.
1. Dextera seeks expanded indications for MicroCutter 5/80 stapler
Dextera Surgical announced in a June 1 press release that it has filed a 510(k) with the FDA for its MicroCutter 5/80 stapler. The company wants to expand the indications of the MicroCutter 5/80 for use in liver, pancreas, kidney and spleen surgeries. Currently, the staplers are used for transection and resection in multiple open minimally-invasive urologic, thoracic and pediatr...
Source: Mass Device - June 2, 2017 Category: Medical Devices Authors: Danielle Kirsh Tags: Business/Financial News Clinical Trials News Well Regulatory/Compliance Research & Development c2 Therapeutics Dextera Surgical DreaMed Diabetes EndoGastric Solutions Inc. Implandata Inolife MicroTransponder Inc. Source Type: news
Medtronic touts CRT study showing heightened medication adherence
Patients implanted with cardiac resynchronization devices showed a greater rate of adherence to their medication regiments after their CRT devices were put it, according to a retrospective study Medtronic (NYSE:MDT) touted today.
The analysis examined data from 4,512 patients who received CRT devices between January 2008 and December 2014, evaluating adherence to recommended medications before and after CRT implantation. Compliance increased 67% 2 years after CRT implantation when compared to 2 years pre-implantation, Fridley, Minn.-based Medtronic said.
“These data support our commitment to understanding how we can...
Source: Mass Device - September 19, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Cardiovascular Clinical Trials Cardiac Rhythm Management Medtronic Source Type: news
MassDevice.com +5 | The top 5 medtech stories for July 8, 2016
Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Nexstim wins CE Mark for brain therapy treatment for chronic neuropathic pain
Brain therapy system developer Nexstim said late last month it won expanded CE Mark approval in the European Union for its Navigated Brain Therapy sy...
Source: Mass Device - July 8, 2016 Category: Medical Equipment Authors: MassDevice Tags: News Well Plus 5 Source Type: news
Nexstim wins CE Mark for brain therapy treatment for chronic neuropathic pain
Brain therapy system developer Nexstim said late last month it won expanded CE Mark approval in the European Union for its Navigated Brain Therapy system, now cleared for the relief of chronic neuropathic pain.
The NBT system uses navigated transcranial magnetic stimulation to treat exact areas in the brain using a 3D image rendered from a patients MRI scan, and has existing clearances for treating major depression and for use in stroke rehabilitation therapy.
“Chronic neuropathic pain is a debilitating condition worldwide with few effective therapeutic options. With our NBT technology we have the potential to make a...
Source: Mass Device - July 8, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Neurological Neuromodulation/Neurostimulation Pain Management Regulatory/Compliance Nexstim Source Type: news
